Diabetology & Metabolic Syndrome-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2024-02-29 苦行僧难上加难来自安大略

昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？

13 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-09-26 ms4000001372213942 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀

38 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-11-27 1df0083fm15(暂无匿称) 来自广东省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。

25 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-05-06 zwwandzl 来自北京

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：糖尿病心肌病;药物治疗
经验分享：3.19投稿
4.14接收
5.6online

65 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-11-30 1471fd7fm79暂无昵称来自辽宁省

记录一下 11.30投稿 3分钟😂 正在initial technical check中

23 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-01-01 ms9000001742428006 来自广东省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：炎症;糖尿病;冠心病
经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！

73 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-03-01 梁小猪

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0
偏重的研究方向：diabetes;metabolic syndrome
经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作

228 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-10-19 祈祈祈祈祈丷

偏重的研究方向：Diabetes
经验分享：20分钟秒拒🍉🍉🍉

76 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-28 Mia

什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104226, encodeId=b301110422673, content=如何回复评审的意见？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 衣谷

如何回复评审的意见？

194 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务